Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study.

Rhinology·2017
Same author

Inhaled allergen challenge in assessment of biologics for asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2013
Same author

Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients.

Allergy·2013
Same author

Sublingual immunotherapy in allergic rhinitis: indications, efficacy and safety.

Rhinology·2013
Same author

A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy.

Allergy·2011
Same author

Activin-A: a novel critical regulator of allergic asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2011

Related Experiment Video

Updated: Jun 22, 2026

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice
07:17

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice

Published on: June 22, 2016

Regulatory T cells and asthma.

D S Robinson1

  • 1Laboratorios Leti, SL, Madrid, Spain. dsrobinson@leti.com

Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology
|June 23, 2009
PubMed
Summary

Regulatory T cells (Tregs) are crucial for suppressing immune responses in asthma. Research shows Tregs are deficient in asthma airways, but enhancing their function offers potential therapeutic strategies.

Area of Science:

  • Immunology
  • Allergy Research
  • Respiratory Medicine

Background:

  • Asthma involves T helper type-2 (Th2) T cell activation, IgE production, and eosinophilia, often linked to allergen responses.
  • Regulatory T cells (Tregs), including CD25(hi), Foxp3(+)Tregs and IL-10-producing Tregs, normally suppress immune responses.
  • Deficiencies in Treg numbers or function are observed in atopic allergic diseases and asthma airways, with reduced Foxp3 expression and impaired CD25(hi) Treg function.

Purpose of the Study:

  • To investigate the role and therapeutic potential of Regulatory T cells (Tregs) in airway inflammation associated with asthma.
  • To explore mechanisms for enhancing Treg development, recruitment, and function within the context of allergic airway disease.
  • To identify potential therapeutic interventions targeting Treg function for asthma treatment.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers
09:15

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers

Published on: July 19, 2024

Related Experiment Videos

Last Updated: Jun 22, 2026

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice
07:17

Phenotypic and Functional Analysis of Activated Regulatory T Cells Isolated from Chronic Lymphocytic Choriomeningitis Virus-infected Mice

Published on: June 22, 2016

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
16:26

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers
09:15

Identification of Rare Antigen-Specific T Cells from Mouse Lungs with Peptide:Major Histocompatibility Complex Tetramers

Published on: July 19, 2024

Main Methods:

  • Analysis of Treg subsets (CD25(hi), Foxp3(+), IL-10-producing) in asthma patients and animal models.
  • Assessment of Treg suppressive function in the context of airway inflammation and hyperresponsiveness.
  • In vitro studies using human T cells to evaluate Treg modulation by various agents.

Main Results:

  • Treg numbers or function may be deficient in patients with atopic allergic diseases and specifically in the airways of asthmatics.
  • Animal models demonstrate that Tregs can suppress established airway inflammation and hyperresponsiveness.
  • Existing therapies (corticosteroids, allergen immunotherapy) and agents like vitamin D3 and long-acting beta-agonists impact Treg function, particularly IL-10 production.

Conclusions:

  • Enhancing Treg function presents a promising therapeutic avenue for managing airway inflammation in asthma.
  • Interventions targeting Treg function, such as those involving IL-10 production or blocking pro-inflammatory pathways, are under investigation.
  • Therapeutic strategies must ensure allergen- or site-specific Treg regulation to avoid suppressing beneficial immune responses.